related substances comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Amino acids: glutamate, aspartate, D-serine, gamma-aminobutyric acid (GABA), glycine Gasotransmitters: nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) Monoamines: Catecholamines: dopamine (DA), norepinephrine (noradrenaline, NE), epinephrine (adrenaline) Indolamines: serotonin (5-HT, SER), melatonin histamine Trace amines: phenethylamine, N-methylphenethylamine, tyramine, 3-iodothyronamine, octopamine, tryptamine, etc. Peptides: oxytocin, somatostatin, substance P, cocaine and amphetamine regulated transcript, opioid peptides Purines: adenosine triphosphate (ATP), adenosine Others: acetylcholine (ACh), anandamide, etc. In addition, over 100 neuroactive peptides have been found, and new ones are discovered regularly. Many of these are co-released along with a small-molecule transmitter. Nevertheless, in some cases, a peptide is the primary transmitter at a synapse. Beta-endorphin is a relatively well-known example of a peptide neurotransmitter because it engages in highly specific interactions with opioid receptors in the central nervous system. Single ions (such as synaptically released zinc) are also considered neurotransmitters by some, as well as some gaseous molecules such as nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S). The gases are produced in the neural cytoplasm and are immediately diffused through the cell membrane into the extracellular fluid and into nearby cells to stimulate production of second messengers.
== History == Both Adolf Jarisch, an Austrian dermatologist, and Karl Herxheimer, a German dermatologist, are credited with the discovery of the Jarisch–Herxheimer reaction. Both Jarisch and Herxheimer observed reactions in patients with syphilis treated with mercury. The reaction was first seen following treatment in early and later stages of syphilis treated with Salvarsan, mercury, or antibiotics. Jarisch thought that the reaction was caused by a toxin released from the dying spirochetes.
Aurich, comprising former East Frisia Hanover, comprising about the former Principality of Calenberg in the Duchy of Brunswick-Lüneburg Hildesheim, comprising the former Brunswick-Lüneburg Principality of Grubenhagen and the former Prince-Bishopric of Hildesheim Lüneburg, comprising the former Brunswick-Lüneburg Principality of Lüneburg and the remainder of Saxe-Lauenburg areas Osnabrück, comprising the former County of Bentheim, the former Lower County of Lingen, and the former Prince-Bishopric of Osnabrück Stade, comprising the former Duchies of Bremen-Verden The Hanoverian subdivisions into high-bailiwicks and bailiwicks remained unchanged until 1 April 1885, when they were replaced by Prussian-style provinces (Regierungsbezirke) and districts (Kreise).
Sulfuryl chloride is an inorganic compound with the formula SO2Cl2. At room temperature, it is a colorless liquid with a pungent odor. Sulfuryl chloride is not found in nature. Sulfuryl chloride is commonly confused with thionyl chloride, SOCl2. The properties of these two sulfur oxychlorides are quite different: sulfuryl chloride is a source of chlorine whereas thionyl chloride is a source of chloride ions. An alternative IUPAC name is sulfuryl dichloride. Sulfur is tetrahedral in SO2Cl2 and the oxidation state of the sulfur atom is +6, as in sulfuric acid.
Sources: en.wikipedia.org
Staley was born as Layne Rutherford Staley on August 22, 1967, at Overlake Hospital in Bellevue, Washington, to Phillip Blair Staley and Nancy Elizabeth Staley (née Layne; later McCallum). Staley disliked his middle name "Rutherford" and would get angry every time someone called him by this name. He legally changed his middle name to "Thomas" during his teens because he was a fan of Mötley Crüe drummer Tommy Lee. Staley joined a rhythm band in Bellevue when he was two or three years old, and was the youngest in the group. At nine years old, he wrote in his Dr. Seuss book, All About Me, that he wanted to be a singer. Staley was seven years old when his parents divorced, after which he was raised by his mother and stepfather, Jim Elmer. He took his stepfather's surname while enrolled in Meadowdale High School in Lynnwood, and was known for some time as Layne Elmer. Staley was raised as a Christian Scientist. However, he was critical of religion in his adult life, stating in a 1991 interview:
== Talent == Global Talent Competitiveness Index (GTCI) 2018: The report analyses the performance of 119 countries and 90 cities worldwide based on six factors: enabling talent, attracting talent, growing talent, retaining talent, vocational and technical skills, and global knowledge skills. Thailand ranked 70 of 119 countries (1=best; 119=worst). Other ASEAN nations ranked were: Singapore, 2; Philippines, 54; Indonesia, 77; Vietnam, 87; Laos, 95; and Cambodia, 108. Bangkok ranked 78 of 90 cities. Global Talent Competitiveness Index (GTCI) 2017: Thailand ranked 73 of 118 countries (1=best; 118=worst). Other ASEAN nations were ranked: Singapore, 2; Malaysia, 28; Philippines, 52; Vietnam, 86; Indonesia, 90; and Cambodia, 108. IMD World Talent Report 2016: This study purports to measure investment in and development of talent and the ability to attract and retain talent. Thailand ranked 37 of 61 nations (1=best; 61=worst), down three spots from 2015. Other ASEAN nations were ranked: Singapore, 15; Malaysia, 19; Indonesia, 44; Philippines, 51.
István Weszprémi Award, University Medical School of Debrecen (1977) Fogarty International Research Fellowship, NIH (1989–1990) Distinguished Scientist Award, Japanese Society for the Promotion of Science (1992) Pándy and Jendrassik Awards, Hungarian Society of Laboratory Medicine (1992, 2000) Széchenyi Professorial Scholarship (1997–2000) Medal for Hungarian Higher Education (1998) Medal of the Hungarian Public Health Scientific Society (2000, 2006) Albert Szent‑Györgyi Medal (2001) Hatvani Award of the City of Debrecen (2005) Semmelweis Award (2006) Öveges Professorial Scholarship (2006) Endre Hőgyes Award (2007) Leó Szilárd Professorial Scholarship (2009) Pro Auditoribus Universitatis Debreceniensis Award (2010) Pro Urbe Award of the City of Debrecen (2011) Krompecher Award, University of Debrecen (2013) Budapest Award (2013) WHO Regional Director’s Award (2019, 2023) H.R. Leavell Award, World Federation of Public Health Associations (2020) Ádám Szendei Award (2020) Officer’s Cross of the Order of Merit of Hungary (2022)
=== Barcode-free hit discovery === Böcker, Pomplun, and colleagues developed a barcode-free hit discovery, wherein the small molecules serve as their own identifiers, acting as the ‘barcodes’ themselves. Known as the Self-Encoded Library (SEL) platform, this approach combines tandem mass spectrometry with custom software called COmbinatorial Mass Encoding Decoding Tool (COMET) for automated structure annotation. By removing the need for external tags, such as the bulky DNA sequences used in traditional DNA-encoded libraries (DELs), the platform eliminates potential interference with target binding and expands the range of compatible chemical reactions. The SEL platform enables direct screening of over half a million small molecules in a single experiment. This platform allowed scientists to identify binders for nucleic acid-binding targets like flap endonuclease 1 (FEN1), a DNA-processing enzyme overexpressed in multiple cancer types that was previously inaccessible to traditional DEL screenings. Furthermore, the platform democratizes drug discovery by utilizing standard mass spectrometry facilities and straightforward synthesis techniques that are accessible to smaller academic laboratories. There are some limitations to the SEL platform. Firstly, there is low scaffold diversity within individual libraries, as the chemistry is limited to the structures compatible with the COMET software. Additionally, SEL hits cannot be amplified, so the amount of material for each potential hit must account for the sensitivity limits of the mass spectrometer.
Greater than 10%: difficulty sleeping, anxiety, nervousness, abdominal pain/cramps, nausea and/or vomiting, low energy, joint/muscle pain, and headache. Less than 10%: loss of appetite, diarrhea, constipation, thirstiness, increased energy, feeling down, irritability, dizziness, skin rash, delayed ejaculation, erectile dysfunction, and chills. A variety of other adverse events have also been reported with less than 1% incidence.
Sources: en.wikipedia.org
==== Supercritical drying ==== To dry the gel, while preserving the highly porous network of an aerogel, supercritical drying employs the use of the liquid-gas transition that occurs beyond the critical point of a substance. By using this liquid-gas transition that avoids crossing the liquid-gas phase boundary, the surface tension that would arise within the pores due to the evaporation of a liquid is eliminated, thereby preventing the collapse of the pores. Through heating and pressurization, the liquid solvent reaches its critical point, at which point the liquid and gas phases become indistinguishable. Past this point, the supercritical fluid is converted into the gaseous phase upon an isothermal de-pressurization. This process results in a phase change without crossing the liquid-gas phase boundary. This method is proven to be excellent at preserving the highly porous nature of the solid network without significant shrinkage or cracking. While other fluids have been reported for the creation of supercritically dried aerogels, scCO2 is the most common substance with a relatively mild supercritical point at 31 °C and 7.4 MPa. CO2 is also relatively non-toxic, non-flammable, inert, and cost-effective when compared to other fluids, such as methanol or ethanol. While being a highly effective method for producing aerogels, supercritical drying takes several days, requires specialized equipment, and presents significant safety hazards due to its high-pressure operation.
Fe3+ + 3 H2O → Fe(OH)3↓ + 3 H+ The iron(III) ion ("ferric iron") can also oxidize pyrite: FeS2(s) + 14 Fe3+ + 8 H2O → 15 Fe2+ + 2 SO2−4 + 16 H+ When iron(III) oxidation of pyrite occurs, the process can become rapid. pH values below zero have been measured in ARD produced by this process. ARD can also produce sulfuric acid at a slower rate, so that the acid neutralizing capacity (ANC) of the aquifer can neutralize the produced acid. In such cases, the total dissolved solids (TDS) concentration of the water can be increased from the dissolution of minerals from the acid-neutralization reaction with the minerals. Sulfuric acid is used as a defense by certain marine species, for example, the phaeophyte alga Desmarestia munda (order Desmarestiales) concentrates sulfuric acid in cell vacuoles.
South Korean immigration policy is relatively unique in that, as a consequence of its claim over the territory currently administered by North Korea, citizens of North Korea are regarded by the South as its own citizens by birth. As a result, North Korean refugees in China often attempt to travel to countries such as Thailand which, while not offering asylum to North Koreans, classifies them as unauthorized immigrants and deports them to South Korea instead of North Korea. At the same time, the policy has operated to prevent pro-North Korea Zainichi Koreans recognised by Japan as Chōsen-seki from entering South Korea without special permission from the South Korean authorities as, despite being regarded as citizens of the Republic of Korea and members of the Korean diaspora, they generally refuse to exercise that status.
polyadenylation The addition of a series of multiple adenosine ribonucleotides, known as a poly(A) tail, to the 3'-end of a primary RNA transcript. A class of post-transcriptional modification, polyadenylation serves different purposes for different classes of RNA and in different cell types and organisms. For eukaryotic messenger RNAs, the addition of a poly(A) tail is an important step in the processing of the raw transcript into a mature mRNA ready for export to the cytoplasm; primary transcripts are first cleaved 10–30 nucleotides downstream of a highly conserved AAUAAA sequence, then the poly(A) tail is generated from the chaining of multiple ATP molecules through the action of polynucleotide adenylyltransferase.For non-coding RNAs and in many bacteria, polyadenylation has the opposite function, instead promoting the RNA's degradation.
== Further reading == Zhu KW (2023). "Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials". Frontiers in Pharmacology. 14 1228548. doi:10.3389/fphar.2023.1228548. PMC 10484631. PMID 37693894.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.